Furthermore, there are indications that four FDA-approved drugs, including Fosaprepitant, Leucal, Fludarabine, and Dantrolene, may possess stronger inhibitory effects on NAT10 than Remodelin, in conclusion, further research is necessary to determine if Remodelin and these four drugs could potentially be used in the treatment of obesity through their ability to inhibit NAT10 [58]. The gene discussed is NAT10; the disease is obesity due to melanocortin 4 receptor deficiency.